Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor (Nasdaq: DXR) has submitted its next-generation blood volume analyzer, Daxor BVA, to the FDA for 510(k) approval. The new device represents a significant advancement in blood volume measurement technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume.
The next-generation analyzer, developed under a U.S. Department of Defense contract, boasts several improvements over its predecessor, the BVA-100™ system, including:
- Three times faster processing
- Significantly simpler operation
- Complete portability
- Point of care analysis capabilities
These enhancements are designed to facilitate seamless integration of advanced blood volume diagnostics into clinical workflows, potentially improving medical care and patient outcomes.
Daxor (DXR) showcased significant presence at the American College of Cardiology's 74th Annual Scientific Session and Expo in Chicago. A key session on Blood Volume Analysis (BVA) versus pressure measurement attracted over 400 clinicians. Duke University Medical Center presented new research confirming BVA as a more precise measure of congestion in heart failure patients.
Dr. Marat Fudim of Duke University Health emphasized that pressure-based assessments often misrepresent true volume status. The Duke study revealed that common proxy markers including urine output, weight change, and biomarkers CA-125 and NT-proBNP did not correlate with intravascular volume. The findings reinforce that volume management, rather than pressure management, should be the primary focus in heart failure treatment.
Daxor (DXR) announces expansion of its blood volume analysis (BVA) technology to three regional healthcare facilities across the U.S. through its Tennessee-based ezBVA Lab service. The expansion includes:
- A Midwest academic medical center for outpatient cardiovascular care
- A Wisconsin primary health center for outpatient syncope assessment
- A Southern New Jersey cardiovascular care program for both inpatient and outpatient settings
The CLIA-certified ezBVA Lab delivers comprehensive BVA results within 24 hours, featuring 98% diagnostic accuracy for tailored fluid management. This expansion demonstrates the growing adoption of Daxor's technology in diverse healthcare settings, aimed at improving patient outcomes while reducing costs.
Daxor (DXR) reported significant growth in its fiscal year 2024, with its Net Asset Value (NAV) increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.
Key highlights include:
- 60.1% growth in diagnostic kit sales
- Addition of 12 new accounts in 2024
- Achievement of cash-flow break-even in Q1 2025
- Securing a $2.5M two-year Department of Defense contract
- Receiving over $350K in NIH and Launch Tennessee grants
The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This new point-of-care system aims to enhance clinical workflows, particularly in critical care settings, and expand market opportunities in both hospital and outpatient environments.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has scheduled an investor conference call for Thursday, March 6, 2025, at 4:30 p.m. ET. During the call, President and CEO Michael Feldschuh and CFO Robert Michel will present the company's fiscal year 2024 financial results and provide updates on corporate developments. The event will include a Q&A session, with investors having the option to submit questions in advance via email. A webcast replay will be available on Daxor.com following the call.
Daxor (DXR) reported significant progress in 2024 and early 2025, with notable financial and operational achievements. The company's net assets reached $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.
Key financial highlights include:
- Revenue growth of 116.5% year-over-year in 2024
- 60.1% increase in diagnostic system kit sales
- 12 new accounts in 2024 and 3 in early 2025
- Operating division achieved cash-flow break-even in Q1 2025
- Secured $2.5M DoD contract and $350K in additional funding
The company entered an agreement to acquire IP from its supplier for in-house manufacturing of Volumex and Glofil products. Daxor is preparing to resubmit FDA 510(k) application for its next-generation blood volume analyzer, which promises faster results and improved functionality. The company aims to transition from an investment company to an operating company designation by the end of 2025.
Daxor (DXR) reported significant progress in 2024 and early 2025, establishing itself as the global leader in blood volume measurement technology. The company achieved notable financial milestones, with net assets reaching $36,789,893 ($7.25 per share) as of December 31, 2024, up from $34,010,384 ($7.08 per share) in 2023.
Key achievements include:
- Revenue growth of 116.5% year-over-year in 2024
- 60.1% increase in diagnostic system kit sales
- 12 new accounts in 2024 and 3 in early 2025
- $2.5M DoD contract and $350K in grants from Launch Tennessee and NIH
- Operating division reached cash-flow break-even in Q1 2025
The company is preparing to launch its next-generation blood volume analyzer, which promises to be three times faster and simpler than current systems. Daxor also entered an agreement to acquire IP from its supplier to bring manufacturing in-house for Volumex and add Glo-fil to its product offerings.
Daxor (DXR) reported significant growth in its fiscal year 2024, with its NAV increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.
Key highlights include:
- 60.1% growth in diagnostic kit sales
- 12 new customer accounts in 2024
- Achievement of cash-flow break-even in Q1 2025 (excluding non-cash expenses)
- Secured $2.5M DoD contract
- Received over $350K in NIH and Launch Tennessee grants
The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This point-of-care system aims to enhance clinical workflows in critical care settings and expand market opportunities in both hospital and outpatient environments.
Daxor (DXR) has expanded its blood volume analysis (BVA) services to a major 735-bed Midwest healthcare facility. The healthcare center will implement Daxor's ezBVA Lab service for outpatient cardiovascular care, focusing on patients with heart failure and hypertension.
Blood samples will be processed at Daxor's CLIA-certified Tennessee facility, providing comprehensive BVA results within 24 hours. The BVA diagnostic offers 98% accuracy in fluid management data, helping clinicians optimize patient care. The service is fully reimbursable through CPT codes for both inpatient and outpatient settings under public and private insurance plans.
Daxor (Nasdaq: DXR) has expanded its blood volume analysis (BVA) technology to two major hospitals within New Jersey's largest academic health care system. The hospitals are implementing on-site BVA analyzers to enable immediate access to precise blood volume measurements for critical care decisions.
The implementation aims to optimize fluid management, reduce hospital stays, and improve outcomes for heart failure and critical care patients. According to CEO Michael Feldschuh, the expansion demonstrates the effectiveness of their growth strategy, with dedicated resources in sales and marketing delivering meaningful results. The company expects to maintain this accelerated sales trajectory throughout 2025.